Abstract
Efficacy of defibrinogenation therapy using Batroxobin on idiopathic sudden sensorineural hearing loss was examined. The results are as follows; 1) The patients whose treatment was started within 10 days of its onset showed complete recovery in 41.1%, improvement in 41.2% and no change in 17.6%. 2) Complete recovery and improvement were also obtained in the group of subacute (11-21 days after the onset) and in that of chronic (more than 22 days) cases. 3) Blood fibrinogen measured during the treatment showed decrease of about 50% of the control level. Simultaneously measured blood viscosity also decreased about 10% of the control level. 4) Treatment was discontinued in 2 out of 52 patients, due to the side effects such as the augmentation of dizziness and the increment of hearing loss. It is concluded that defibrinogenation therapy can be a useful tool for the treatment of idiopathic sudden hearing loss.
